Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

The study's authors emphasized the importance of interventions such as patient communication and education. 

preCARDIA announced that its catheter-based system for acutely decompensated heart failure has received the FDA’s breakthrough device designation.

With the disease becoming more and more common in the United States, researchers have been hard at work determining the best possible treatment options.

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

Rheumatoid arthritis is associated with a greater risk of heart failure, according to new findings published in the Journal of the American Heart Association. The risk increases even more when patients have higher levels of C-reactive protein, a telltale sign of severe inflammation.